November 14, 2000
GENELABS TECHNOLOGIES, INC. REPORTS THIRD QUARTER AND NINE MONTH 2000 FINANCIAL RESULTS

November 13, 2000
WATSON PHARMACEUTICALS AND GENELABS TECHNOLOGIES ENTER INTO COLLABORATION AND LICENSE AGREEMENT FOR LUPUS DRUG

October 31, 2000
GL701 (PRASTERONE) SIGNIFICANTLY REDUCES LUPUS FLARES

October 31, 2000
ASLERA™ IMPROVES BONE MINERAL DENSITY IN LUPUS PATIENTS

October 31, 2000
ASLERA™ IMPROVES LUPUS DISEASE ACTIVITY AND SYMPTOMS

October 25, 2000
FDA ASSIGNS PRIORITY REVIEW DESIGNATION TO GENELABS ASLERA™ FOR LUPUS

September 26, 2000
GENELABS COMPLETES SUBMISSION OF NEW DRUG APPLICATION TO FDA FOR LUPUS TREATMENT

August 24, 2000
GENELABS INTRODUCES MANAGEMENT TEAM MEMBERS

August 10, 2000
GENELABS TECHNOLOGIES, INC. REPORTS SECOND QUARTER AND SIX MONTH 2000 FINANCIAL RESULTS

June 23, 2000
GENELABS DATA SHOWS GL701 IMPROVES OR STABILIZES LUPUS DISEASE ACTIVITY -- DATA ON POTENTIAL NEW HORMONE THERAPY PRESENTED AT ENDO® 2000

May 31, 2000
GENELABS SUBMITS CLINICAL SECTIONS OF NEW DRUG APPLICATION TO FDA FOR LUPUS TREATMENT

May 9, 2000
GENELABS TECHNOLOGIES, INC. REPORTS FIRST QUARTER 2000 FINANCIAL RESULTS

April 20, 2000
GENELABS DISCLOSES DISCOVERY OF A NOVEL CLASS OF ANTIVIRAL COMPOUNDS FROM ITS RNA-BINDING PROPRIETARY TECHNOLOGY

April 17, 2000
GENELABS TECHNOLOGIES, INC. TO PRESENT DATA ON NOVEL ANTIVIRAL COMPOUNDS FROM ITS PROPRIETARY TECHNOLOGY AT INTERNATIONAL ANTIVIRAL CONFERENCE

March 31, 2000
GENELABS TECHNOLOGIES, INC. REPORTS 1999 YEAR-END AND FOURTH QUARTER FINANCIAL RESULTS

March 3, 2000
GENELABS TECHNOLOGIES, INC. COMMENTS ON BIO-RAD LABORATORIES' PATENT SUIT AGAINST SINGAPORE-BASED GENELABS DIAGNOSTICS PTE. LTD.

February 25, 2000
DR. ROBERT LAHITA PRESENTS DATA ON GENELABS GL701 IN LUPUS AT AMERICAN COLLEGE OF RHEUMATOLOGY MEETING.

February 14, 2000
GENELABS REPORTS STATISTICALLY SIGNIFICANT PHASE III TRIAL RESULTS FOR GL701 IN LUPUS AT AUTOIMMUNITY CONFERENCE --Benefits Extend to Bone Density--.

February 3, 2000
GENELABS RECEIVES $5 MILLION FOR DARPA RESEARCH IN 2000- Drug Discovery Grant Renewed for Third Year.

© Genelabs Technologies, Inc. All rights reserved. - Terms of Use